Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Therapy in Resected Stage IA2-II NSCLC With Undetectable MRD
NCT06924710Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Apr 2025
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Disease Free Survival at 2 years. Started Apr 2025; status: recruiting.
Beyond the preview
Go deeper on NCT06924710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924710.